International Myeloma Working Group Recommendations for Global Myeloma Care

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Nov 2

PMID 24177258

Citations 69

Authors

H Ludwig

J S Miguel

M A Dimopoulos

A Palumbo

R Garcia Sanz

R Powles

S Lentzsch

W Ming Chen

J Hou

A Jurczyszyn

K Romeril

R Hajek

E Terpos

K Shimizu

D Joshua

V Hungria

A Rodriguez Morales

D Ben-Yehuda

P Sondergeld

E Zamagni

B Durie

Affiliations

Soon will be listed here.

Abstract

Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

Citing Articles

EANM guidelines on the use of [F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Nanni C, Deroose C, Balogova S, Lapa C, Withofs N, Subesinghe M Eur J Nucl Med Mol Imaging. 2024; 52(1):171-192.

PMID: 39207486 PMC: 11599630. DOI: 10.1007/s00259-024-06858-9.

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma.

Hussain Z, De Brouwer E, Boiarsky R, Setty S, Gupta N, Liu G NPJ Digit Med. 2024; 7(1):200.

PMID: 39075240 PMC: 11286964. DOI: 10.1038/s41746-024-01189-3.

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma.

Nadeem O, Ailawadhi S, Khouri J, Williams L, Catamero D, Maples K Cancers (Basel). 2024; 16(5).

PMID: 38473381 PMC: 10930695. DOI: 10.3390/cancers16051023.

Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients.

Hamdaoui H, Nouadi B, Benlarroubia O, Chbel F, Saadoune C, Bennis F Leuk Res Rep. 2023; 20:100392.

PMID: 38035181 PMC: 10685041. DOI: 10.1016/j.lrr.2023.100392.

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.

McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell T Adv Ther. 2023; 40(10):4626-4638.

PMID: 37597153 PMC: 10499666. DOI: 10.1007/s12325-023-02623-w.

References

Alexanian R, Dimopoulos M, Delasalle K, Barlogie B . Primary dexamethasone treatment of multiple myeloma. Blood. 1992; 80(4):887-90. View

Spencer A, Prince H, Roberts A, Prosser I, Bradstock K, Coyle L . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009; 27(11):1788-93. DOI: 10.1200/JCO.2008.18.8573. View

Hussein M, Vrionis F, Allison R, Berenson J, Berven S, Erdem E . The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 2008; 22(8):1479-84. DOI: 10.1038/leu.2008.127. View

Lokhorst H, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers M . A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2009; 115(6):1113-20. DOI: 10.1182/blood-2009-05-222539. View

Palumbo A, Rajkumar S, Dimopoulos M, Richardson P, San Miguel J, Barlogie B . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2007; 22(2):414-23. DOI: 10.1038/sj.leu.2405062. View

Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M . Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia. 2011; 26(1):73-85. DOI: 10.1038/leu.2011.310. View

Mellqvist U, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K . Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013; 121(23):4647-54. PMC: 3674665. DOI: 10.1182/blood-2012-11-464503. View

Cavo M, Pantani L, Petrucci M, Patriarca F, Zamagni E, Donnarumma D . Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120(1):9-19. DOI: 10.1182/blood-2012-02-408898. View

Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M . Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk. 2012; 12(6):423-32. DOI: 10.1016/j.clml.2012.06.008. View

10.

Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N . Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2011; 97(3):442-50. PMC: 3291601. DOI: 10.3324/haematol.2011.043372. View

11.

Mileshkin L, Stark R, Day B, Seymour J, Zeldis J, Prince H . Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006; 24(27):4507-14. DOI: 10.1200/JCO.2006.05.6689. View

12.

Morgan G, Davies F, Gregory W, Russell N, Bell S, Szubert A . Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011; 118(5):1231-8. PMC: 3152492. DOI: 10.1182/blood-2011-02-338665. View

13.

Badros A, Vij R, Martin T, Zonder J, Kunkel L, Wang Z . Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013; 27(8):1707-14. PMC: 3740399. DOI: 10.1038/leu.2013.29. View

14.

Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102(5):1115-23. DOI: 10.1046/j.1365-2141.1998.00930.x. View

15.

Broyl A, Corthals S, Jongen J, van der Holt B, Kuiper R, de Knegt Y . Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010; 11(11):1057-65. DOI: 10.1016/S1470-2045(10)70206-0. View

16.

Ng A, Kumar S, Rajkumar S, Drake M . Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009; 84(7):397-400. PMC: 2895403. DOI: 10.1002/ajh.21412. View

17.

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

18.

Dimopoulos M, Kastritis E, Rosinol L, Blade J, Ludwig H . Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008; 22(8):1485-93. DOI: 10.1038/leu.2008.131. View

19.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C . Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118(22):5752-8. DOI: 10.1182/blood-2011-05-355081. View

20.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-91. DOI: 10.1056/NEJMoa1114138. View